RIDE-001 was developed using Trained Therapeutix’s proprietary ApoA1-based nanomedicines platform to target the bone marrow where it activates the intracellular pattern recognition receptor NOD2. This ...
Only 30% of patients who start GLP-1s for weight loss are still using them after one year, with GI side effects cited as the #1 cause of treatment discontinuation NG101 is a first-in-class therapy ...
Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced the receipt of ...
(Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, will host an R&D Day on Monday, November 10, 2025 at 8:00 a.m. ET in New York City featuring ...
Interim data from the IQIRVO ® (elafibranor) ELATIVE long-term open label extension trial demonstrate sustained biochemical response, stabilization of fibrosis markers and consistent trends in ...
AI-based digital pathology analysis provides high-resolution quantification of hepatic fibrosis and objective measurement of fibrosis improvement. Pemvidutide demonstrated signifi ...
Demonstrates PPARG inhibition as a potential strategy to overcome immune resistance in advanced UC − Supports the planned Phase 1 cohort of FX-909 in combination with pembrolizumab; initiating in the ...
In mice bearing poorly immunogenic EMT6 tumors, a sequential regimen of mWTX-330 (IL-12) followed by WTX-124 (IL-2) was well tolerated and demonstrated superior tumor-killing ability compared to ...
Nouscom Presents New Positive Phase 1/2b data of NOUS-209 at SITC 2025, Supporting Plans to Initiate Registration-Enabling Study for Cancer Interception in Lynch Syndrome Carriers New data from Phase ...
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation therapies to treat cancer and immune disorders, today announced the ...
Live webcasts of the presentations will be available on the " Events & Presentations " page of the "Investors" section of the Celldex website. Replays will be available for 90 days following the event ...
Live webcasts of the analyst-led fireside chats can be accessed by visiting “Investor Events” on the Investors section of the Wave Life Sciences website: ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback